US2011124580A1PendingUtilityA1

Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto

Assignee: HARVARD COLLEGEPriority: Sep 11, 1998Filed: Mar 22, 2010Published: May 26, 2011
Est. expirySep 11, 2018(expired)· nominal 20-yr term from priority
A61P 43/00A61P 35/00C12N 5/0688A61K 38/1709A61P 11/00C07K 14/46
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application relates to a method for modulating the growth state of an lung tissue, or a cell thereof, e.g., by ectopically contacting the tissue, in vitro or in vivo, with a hedgehog therapeutic, a ptc therapeutic, or an FGF-10 therapeutic in an amount effective to alter the rate (promote or inhibit) of proliferation of cells in the lung tissue, e.g., relative to the absence of administration of the hedgehog therapeutic or ptc therapeutic. The subject method can be used, for example, to modulate the growth state of epithelial and/or mesenchymal cells of a lung tissue, such as may be useful as part of a regimen for prevention of a disease state, or in the treatment of an existing disease state or other damage to the lung tissue.

Claims

exact text as granted — not AI-modified
1 . A method for modulating the growth state of lung tissue, or cells derived therefrom, comprising ectopically contacting the tissue with an amount of an agent effective to alter the rate of proliferation of the lung tissue, wherein the agent is selected from the group consisting of a hedgehog therapeutic, a ptc therapeutic and an fgf-10 therapeutic. 
     
     
         2 . A method for inducing the formation of, or the maintenance or function a performance of lung tissue, comprising contacting the lung tissue with an amount of an agent effective to induce the formation of new lung tissue, wherein the agent is selected from the group consisting of a hedgehog therapeutic, a ptc therapeutic and an fgf-10 therapeutic. 
     
     
         3 . The method of  claim 1 , wherein the lung tissue is in culture, and the agent is provided as a cell culture additive. 
     
     
         4 . The method of  claim 1 , wherein the cell is treated in an animal and the agent is administered to the animal as a therapeutic composition. 
     
     
         5 . The method of  claim 1 , wherein the agent is a hedgehog therapeutic. 
     
     
         6 . The method of  claim 5 , wherein the hedgehog therapeutic is a polypeptide including a hedgehog polypeptide sequence of at least a bioactive extracellular portion of a hedgehog protein. 
     
     
         7 . The method of  claim 6 , wherein the polypeptide includes at least 50 amino acids residues of an N-terminal half of the hedgehog protein 
     
     
         8 . The method of  claim 6 , wherein the polypeptide includes at least 100 amino acids of an extracellular domain of the hedgehog protein. 
     
     
         9 . The method of  claim 6 , wherein the polypeptide includes at least a portion of the hedgehog protein corresponding to a 19 kd fragment of an extracellular domain of the hedgehog protein. 
     
     
         10 . The method of  claim 6 , wherein the hedgehog protein is encoded by a gene of a vertebrate organism. 
     
     
         11 . The method of  claim 6 , wherein the polypeptide includes a hedgehog polypeptide sequence represented in the general formula of SEQ ID No. 21. 
     
     
         12 . The method of  claim 6 , wherein the polypeptide includes a hedgehog polypeptide sequence represented in the general formula of SEQ ID No. 22. 
     
     
         13 . The method of  claim 6 , wherein the hedgehog protein is encoded by a human hedgehog gene. 
     
     
         14 . The method of  claim 6 , wherein the hedgehog polypeptide sequence is at least 60 percent identical to an amino acid sequence of a hedgehog protein selected from the group consisting of SEQ ID No:9, SEQ ID No:10, SEQ ID No:11, SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15 and SEQ ID No:16. 
     
     
         15 . The method of  claim 6 , wherein the hedgehog polypeptide sequence is encodable by a nucleotide sequence which hybridizes under stringent conditions to a sequence selected from the group consisting of SEQ ID No:1, SEQ ID No:2, SEQ ID No:3, SEQ ID No:4, SEQ ID No:5, SEQ ID No:6, SEQ ID No:7 and SEQ ID No:8. 
     
     
         16 . The method of  claim 6 , wherein the hedgehog polypeptide sequence is an amino acid sequence of a hedgehog protein selected from the group consisting of SEQ ID No:9, SEQ ID No:10, SEQ ID No:11, SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15 and SEQ ID No:16. 
     
     
         17 . The method of  claim 6 , wherein the hedgehog polypeptide sequence is an amino acid sequence of a Sonic hedgehog protein. 
     
     
         18 . The method of  claim 1 , wherein the agent is a ptc therapeutic. 
     
     
         19 . The method of  claim 18 , wherein the ptc therapeutic is a small organic molecule which binds to a patched protein and derepresses patched-mediated inhibition of mitosis. 
     
     
         20 . The method of  claim 18 , wherein the ptc therapeutic binds to patched and mimics hedgehog-mediated patched signal transduction. 
     
     
         21 . The method of  claim 20 , wherein the ptc therapeutic is a small organic molecule.

Join the waitlist — get patent alerts

Track US2011124580A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.